Is PHMMF Stock Undervalued?

A comprehensive valuation analysis of Pharma Mar SAU (PHMMF) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated July 17, 2026•8 min read•View Full Analysis

Valuation Verdict

→

Fairly Valued

0.0% downside risk

Based on our analysis, Pharma Mar SAU appears to be fairly valued at the current price of $0.00.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing PHMMF relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

69.60

High

P/B Ratio

N/A

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: At 69.60x earnings, PHMMF is trading above the typical market average of 15-20x.
P/B Ratio: Book value data not available.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Pharma Mar SAU stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$0.00

Fair Value Estimate

N/A

Unable to calculate a reliable fair value estimate due to insufficient financial data or negative cash flows. This is common for early-stage growth companies or those undergoing restructuring.

Historical Valuation Trends

Looking at PHMMF's valuation history helps us understand whether the current multiples are typical or unusual for this company.

Current P/E Ratio

69.60

5-Year Average P/E

69.60

Near historical average

PHMMF's P/E ratio is near its historical average, indicating the market is valuing the company consistently with past trends.

Investment Conclusion

Bottom Line

Pharma Mar SAU (PHMMF) appears fairly valued at $0.00, trading in line with our fundamental analysis. The stock may be appropriate for investors seeking exposure to Healthcare without significant valuation risk.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.